28.4 C
Vientiane
Wednesday, September 3, 2025
spot_img
Home Blog Page 447

OutSystems Unveils Agent Workbench to Accelerate Enterprise AI Innovation

OutSystems Agent Workbench empowers organizations to create custom AI agents that streamline operations, elevate experiences, and grow revenue 

SINGAPORE, July 16, 2025 /PRNewswire/ — OutSystems, a leading AI-powered low-code development platform, today announced the Early Access Program for OutSystems Agent Workbench. Agent Workbench enables enterprises to create and orchestrate intelligent agents for any use case—and across any department, workflow, or data—with enterprise-grade security and control. Delivered on OutSystems trusted platform, Agent Workbench makes it easier than ever for pragmatic leaders to innovate at speed and orchestrate human-AI collaboration.

“Organizations are excited by the promise of AI and agentic systems, but are struggling with endless pilots and ungoverned tool sprawl while the business impact stalls. Legacy systems, siloed data, fragmented AI tools, and complex AI development cycles are slowing progress,” said Woodson Martin, CEO of OutSystems. “We built Agent Workbench to make it possible to unlock custom agents as a true business enabler—not an experiment.”

With everything organizations need to create and scale enterprise-grade agents, OutSystems Agent Workbench simplifies the transformation of existing business applications, workflows, and tools into intelligent, agentic systems that can reason, plan, and act.

IT teams can embed agentic AI into enterprise-wide operations without disrupting current workflows or rearchitecting core systems—accelerating adoption and time to value. From connecting to custom AI models to creating and orchestrating agents that work across all enterprise applications and data, Agent Workbench makes AI a driver of enterprise innovation. With Agent Workbench, organizations of any size can:

  • Build and scale AI agents that work across the entire enterprise effortlessly and safely for real-time goal interpretation, option evaluation, and decision-making, while controlling tool sprawl through a single platform.
  • Seamlessly integrate with custom AI models or leading third-party providers like Azure OpenAI and AWS Bedrock to centralize control over AI and data access, decrease cost, and enable multi-vendor utilization.
  • Ground AI agents with a unified data fabric that connects to diverse enterprise data sources, such as existing OutSystems 11 data and actions, relational databases, data lakes, knowledge retrieval systems like Kendra and Azure AI Search, and even agent memory of past interactions, to ensure accurate and context-rich responses across workflows.
  • Orchestrate multi-agent workflows where agents dynamically adjust process flows based on an understanding of all enterprise systems, with real-time context, reasoning, and decisions to tackle complex tasks—whether working in parallel, sequentially, or hierarchically. This enables collaborative task execution, escalation handling, and human intervention when necessary.
  • Monitor agent performance enterprise-wide with real-time logging, error tracing, and built-in guardrails to ensure transparent, reliable decision-making. Gain full visibility into how AI agents operate at every step—making it easy to audit, troubleshoot behavior, and prevent hallucinations, while building trust through explainability and control.

Sign up for the  OutSystems Agent Workbench Early Access Program here. OutSystems Agent Workbench will be generally available later this year. To learn more, visit the OutSystems Agent Workbench page.

About OutSystems 

OutSystems is a leading AI-powered low-code development platform, empowering IT leaders with a better way to build the software that matters most. The OutSystems platform helps companies develop, deploy, and maintain mission-critical applications by unifying and automating the entire software lifecycle. With OutSystems, organizations leverage gen AI to deliver software instantaneously, adapt faster to changing requirements, and reduce technical debt by building on a future-proof platform. Helping customers achieve their business goals by addressing key strategic initiatives, OutSystems delivers production software up to 10x faster than traditional development. Recognized as a leader by analysts, IT executives, business leaders, and developers around the world, global brands trust OutSystems to tackle their impossible projects and turn their big ideas into software that moves their business, people, and the world forward. Founded in 2001, the company’s network spans more than 800,000 community members, over 500 partners, and active customers in 75+ countries across 21 industries. Learn more at www.outsystems.com.

Otis Enhances Luxury Living with Sustainable and Innovative Mobility Solutions

  • Smart connected solutions with energy saving regenerative drive technology

KUALA LUMPUR, Malaysia, July 16, 2025 /PRNewswire/ — Otis (NYSE: OTIS) will provide innovative technology and connected vertical mobility solutions for Arte Star, a luxury residential building located near iconic landmarks such as the Kuala Lumpur Tower and Merdeka 118.

  • Otis will complete installation of 22 SkyRise® and 1 Gen3™ elevator systems by 2027
  • Otis will maintain Arte Star’s vertical mobility systems through 2029
  • Otis is the world’s leading elevator and escalator manufacturing, installation, and service company

“We are proud to collaborate with our customer Arte Corp on this project, delivering smarter, safer and more sustainable solutions that enhance Kuala Lumpur’s urban landscape and redefine luxury living,” said Pradeep Nair, Managing Director of Otis Malaysia and Brunei.

FAQ: What Otis systems will be in the Arte Star, Kuala Lumpur?

  • The flexible SkyRise system, available in a range of speeds and rises up to 900m, is equipped with the Otis regenerative-drive technology (ReGen® Drive) which feeds electrical energy back into the building power grid during braking. This can then be used to power equipment in the building, helping to lower net electricity consumption and enable building cost savings
  • The Gen3 elevator system launched in Malaysia in 2024, is digitally connected. It enables real-time monitoring, predictive maintenance, and seamless building integration. The Gen3 elevator system enhances efficiency, improves safety, and elevates the customer’s experience  
  • The Arte Star will be equipped with the Otis ONE™ IoT digital platform that connects elevators to the cloud. Otis ONE monitors, collects and analyzes data from elevators’ smart sensors to deliver performance information, proactive communication and predictive insights to Otis’ customers. This translates to improved savings and value for building owners and managers.

About Otis

Otis gives people freedom to connect and thrive in a taller, faster, smarter world. The global leader in the manufacture, installation and servicing of elevators and escalators, we move 2.4 billion people a day and maintain approximately 2.4 million customer units worldwide – the industry’s largest Service portfolio. You’ll find us in the world’s most iconic structures, as well as residential and commercial buildings, transportation hubs and everywhere people are on the move. Headquartered in Connecticut, USA, Otis is 72,000 people strong, including 44,000 field professionals, all committed to manufacturing, installing and maintaining products to meet the diverse needs of our customers and passengers in more than 200 countries and territories. To learn more, visit www.otis.com and follow us on LinkedIn, Instagram and Facebook @OtisElevatorCo.

OceanX Education Welcomes Science Engagement Leader Prof. Tit Meng Lim as APAC Regional Executive Director

Renowned science educator and regional champion of STEM to lead OceanX Education’s expansion and mission across Asia

SINGAPORE, July 16, 2025 /PRNewswire/ — OceanX Education is proud to announce the upcoming appointment of Professor Tit Meng Lim as its new APAC Regional Executive Director. Based in Singapore, Prof. Lim will lead the organization’s growth and outreach efforts across Asia, guiding strategic vision, regional partnerships, and organizational development at a pivotal time for ocean literacy and environmental engagement.

Prof. Tit Meng Lim, APAC Regional Executive Director, OceanX Education
Prof. Tit Meng Lim, APAC Regional Executive Director, OceanX Education

A household name in science education and public engagement, Prof. Lim brings more than 30 years of leadership experience spanning academia, government-linked institutions, and international science networks. He most recently served as Chief Executive of the Science Centre Singapore, where he oversaw national efforts to promote STEM innovation and led the transformation of science learning into vibrant, community-driven experiences.

Prof. Lim also held leadership roles at the National University of Singapore for over two decades, including Vice Dean of the Faculty of Science, where he was instrumental in shaping interdisciplinary science curricula and advancing life sciences education. His influence extends beyond Singapore through board leadership positions with organizations such as the Asia Pacific Network of Science & Technology Centres and the Association of Science-Technology Centres (ASTC).

“Tit Meng is a visionary,” said Mark Dalio, Founder and Executive Chairman, OceanX Education. “His ability to bridge science, education, public engagement, and cross-cultural collaboration is unmatched. We’re excited to work with him to grow OceanX Education’s impact in Asia and build a dynamic, inclusive future for ocean learning.”

In his role as APAC Regional Executive Director, Prof. Lim will spearhead efforts to scale OceanX Education’s footprint in the region, from establishing new programs that blend science, education, immersive storytelling, and public programming, to building institutional partnerships and long-term funding strategies. He will also oversee operations, organizational planning, and the expansion of OceanX Education’s regional team.

“OceanX Education stands at the crossroads of science, media, and mission-driven innovation,” said Prof. Lim. “To be part of building a movement that brings the ocean to life for learners across the region is deeply meaningful. I’m honored to help lead this next chapter.”

This appointment marks a significant milestone in OceanX Education’s global strategy, reinforcing its presence in Asia and commitment to developing the next wave of ocean leaders.

For more information about OceanX’s ongoing work, please visit the OceanX website . For media inquiries regarding OceanX, please contact Karuna Tuli at karuna.tuli@oceanx.org .

About OceanX

OceanX is a nonprofit working to unlock the ocean’s sustainable potential. Through a dual focus on science and education, we’re building a new paradigm where humanity and the ocean mutually thrive. Our approach is fueled by exploration, leveraging advanced research, multimedia educational programs, cross-sector partnerships, and advanced technology to help transform how people understand and value the ocean. Our work strives to fortify biodiversity and increase the sustainable use of ocean resources to help ensure the ocean remains a foundation for human wellbeing and potential. OceanX is a nonprofit operating program of Dalio Philanthropies. For more information, visit www.oceanx.org and follow OceanX on Facebook, Instagram, X (formerly Twitter), TikTok, LinkedIn, and  YouTube.

 

New Azul and ITAM Forum Survey Reveals 1 in 4 Organizations Spend More Than $500,000 Annually Resolving Software License Non-Compliance

73% of enterprises have experienced an Oracle Java audit within the last three years and almost 8 in 10 organizations have migrated, or plan to migrate, to open-source Java alternatives

SINGAPORE, July 16, 2025 /PRNewswire/ — Azul, the only company 100% focused on Java, and the ITAM Forum, a global not-for- profit membership association for IT Asset Management (ITAM) professionals, today published the results of a joint global survey of 500 ITAM and software asset management (SAM) professionals. The results show just how costly software license missteps have become: 27% of enterprises now spend more than $500,000 each year fixing software-license non-compliance and Oracle Java continues to escalate as a top concern, with 73% having undergone an Oracle Java audit within the past three years and nearly eight in 10 saying they have migrated, or intend to migrate, to open-source Java alternatives to rein in risk and cost.

Behind those numbers lies a growing challenge. Hybrid cloud architectures and an increasing inventory of applications have multiplied vendor terms, making it harder than ever to maintain compliance and visibility across teams. The survey confirms organizations struggle to track usage consistently, both on-premises and in the cloud, raising the stakes for audits and exposing costly gaps. In this environment, the scope and importance of ITAM and SAM functions, as well as the tools and processes they depend on, have shifted from simple asset tracking to a business-critical discipline that safeguards budgets, mitigates audit risk and guides strategic technology decisions.

Organizations Struggle to Manage Software Licensing Compliance

More than a third of survey participants say compliance, including the management of excessive licensing, is the top issue facing their organization (37%). In addition to the dollars spent each year resolving licensing issues – including audits, additional licenses and penalties – survey participants report that complex software configurations make tracking application usage more difficult (25%). Compliance requires knowledge of where the software is installed, what is running, and where the information is managed. ITAM/SAM professionals report that their organizations struggle to manage this information, especially when tracking software usage across teams or between on-premises and cloud platforms (29%).

Additional challenges relating to managing software licensing and compliance include:

  • Difficulty in aligning teams, including IT, software development, legal, and procurement (27%).
  • Resource constraints to effectively manage license compliance (24%).
  • Escalating prices, including renewals, additional licenses, maintenance, etc. (24%).
  • Ensuring compliance with evolving licensing rules or vendor policy updates (23%).

Most Organizations Handle Audits Internally, Yet Struggle with Accuracy, Resources and Repeated Disruptions

ITAM/SAM professionals cite challenges with coordination, collaboration and organization in their efforts to track software inventory, yet 74% of survey participants say their organization manages license discovery and software audits primarily or entirely in-house. This self-reliant approach comes with difficulties, as organizations struggle to maintain accurate software usage records (26%), understand complex licensing terms and conditions (23%), and provide accurate licensing compliance metrics (23%). In addition, 81% of organizations perform licensing audits at least twice a year, with 25% conducting audits continuously. About a quarter report frequent financial penalties and legal actions against them.  

Survey participants also cite that software audits are highly disruptive, both operationally and financially. More than 30% report unanticipated results such as:

  • Disruption of operations across the entire organization.
  • Unexpected budget impacts.
  • Decision to change vendors.
  • Stalled projects.

Oracle Java Audit Pressures Drive Mass Migration

The survey reveals acute Oracle Java licensing challenges – in addition to the high number of respondents who have experienced Oracle Java audits, 96% expressed concern about Oracle’s pricing and licensing policies. Much of this stems from Oracle’s employee-based pricing model for Java, which is forcing companies that do not intend to pay Oracle to invest in new monitoring systems, tracking tools and internal audit processes to ensure they have eliminated all Java instances that require an Oracle license.

In response to concerns about Oracle’s pricing and licensing policies, 79% of organizations have already migrated from Oracle Java, are actively doing so, or are planning to migrate to open-source alternatives. Those considering migration cited security and reliability as the primary drivers (51%), followed by cost reduction (42%) and simpler compliance (40%). Among organizations that have already completed migrations, security played an even larger role, with 57% citing security and reliability as their primary motivation.

Cost savings from open-source Java alternatives are substantial, with 66% of survey participants estimating they could save at least 40% compared to Oracle Java licensing costs. Only 1% expect they would not realize any savings from making the switch.

Growing Market Reflects Escalating Challenges

The findings come as the global ITAM market has grown from approximately $1.15 billion in 2019 to $1.49 billion in 2023[1], representing a 6.9% compound annual growth rate. The SAM market subset is expected to grow at an even faster 16% compound annual growth rate through 2029[2], reflecting the complexity and importance of software asset management.

Contributing factors include rising software expenditures (now accounting for, on average, 29% of IT budgets), complex licensing models driven by cloud computing and virtualization, and increasing regulatory compliance requirements.

“The results highlight a fundamental mismatch between the complexity of modern software licensing and the resources organizations rely on to effectively manage software compliance,” said Martin Thompson, founder of the ITAM Forum. “ITAM and SAM professionals are becoming increasingly vital as organizations increasingly recognize that poor license management can result in significant financial penalties and operational disruptions. They must have the resources and executive buy-in to ensure compliance and successful license management.”

“The data reveals a concerning trend where the increasing complexity of vendor licensing and pricing has turned routine upkeep into recurring six-figure compliance exercises. When 73% of enterprises have been audited and one in four now spends more than $500,000 a year cleaning up license issues, the cost of merely staying compliant with software licensing and pricing is unsustainable,” said Scott Sellers, co-founder and CEO at Azul. “Specifically, when it comes to the uncertainty of Oracle’s ever-shifting Java licensing terms, organizations shouldn’t have to burn ITAM resources, interrupt projects, or absorb surprise penalties just to run their applications. Moving to open-source alternatives lets them break free from the audit treadmill, regain budget and focus on delivering value.”

About the Survey and Report

Dimensional Research, a leading market research firm, administered the electronic survey from February 11 – March 3, 2025. ITAM Forum and Azul authored the report based on the survey results. The report data was compiled from a total of 500 IT Asset Management and Software Asset Management professionals across six continents who use Java. All respondents had direct software asset management responsibilities and were offered token compensation for their participation.

To access the full ITAM/SAM Survey & Report, visit azul.com/what-keeps-itam-sam-leaders-up-at-night/.

About The ITAM Forum

The ITAM Forum is a global trade body for the advancement of the IT Asset Management industry. We are a not-for-profit membership organization, led by ITAM professionals for ITAM professionals. The ITAM Forum has two primary objectives: 1. To elevate the position of ITAM by sharing knowledge and best practices that focus on business value and aid to grow the profession. 2. To be the caretaker of the ISO 19770-1 certification scheme we brought to market in February 2023. Join us: www.itamf.org

About Azul

Headquartered in Sunnyvale, California, Azul provides the Java platform for the modern cloud enterprise. Azul is the only company 100% focused on Java. Millions of Java developers, hundreds of millions of devices and the world’s most highly regarded businesses trust Azul to power their applications with exceptional capabilities, performance, security, value, and success. Azul customers include 36% of the Fortune 100, 50% of Forbes top 10 World’s Most Valuable Brands, 10 of the world’s top 10 banks, and leading brands like Avaya, Bazaarvoice, BMW, Deutsche Telekom, LG, Mastercard, Mizuho, Priceline, Salesforce, Software AG and Workday. Learn more at azul.com  and follow us @azulsystems.

 

Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

HONG KONG, July 16, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) is pleased to announce that the first patient has been successfully enrolled in the registration Phase III clinical trial (AK112-312/HARMONi-GI6) of ivonescimab in first-line treatment for advanced metastatic colorectal cancer (mCRC).

This randomized, controlled, multi-center Phase III clinical trial for first-line treatment of mCRC is one of the company’s key initiatives to address the significant unmet clinical need worldwide with ivonescimab.

Colorectal cancer remains the third most common cancer globally and the second leading cause of cancer-related deaths. In 2022, over 1.9 million new cases were reported, with approximately 904,000 deaths. Of these, about 95% of mCRC cases are classified as microsatellite stable (MSS) or proficient mismatch repair (pMMR), which traditionally show poor responses to immunotherapy and the tumors are often referred to as an “immune desert.”

For first-line treatment of MSS/pMMR-type mCRC, which represents up to 95% of cases, several PD-1/L1 inhibitors have been explored in multiple international studies. However, the efficacy has been limited, and as of now, no first-line immunotherapy has been approved globally for patients with pMMR/MSS-type mCRC.

Chemotherapy combined with targeted therapies (such as bevacizumab, cetuximab, etc.) remains the standard first-line treatment for mCRC, though its overall efficacy is limited, with a five-year survival rate for advanced patients of less than 20%. Bevacizumab is the most well-established and clinically impactful treatment in the mCRC space. It is also one of the core indications of bevacizumab.

At the 2024 European Society for Medical Oncology (ESMO) Congress, Professor Yanhong Deng from the Sixth Affiliated Hospital of Sun Yat-sen University, presented promising Phase II efficacy data of ivonescimab in combination with chemotherapy for first-line treatment of MSS/pMMR-type mCRC.

The combination of ivonescimab with FOLFOXIRI demonstrated compelling anti-tumor activity in this hard to treat patient population, with an overall response rate (ORR) of 81.8% and a disease control rate (DCR) of 100%. After a median follow-up of 9 months, the median progression-free survival (mPFS) was not reached, with a 9-month PFS rate of 81.4%. Regardless of KRAS/BRAF mutation status, patients can benefit from ivonescimab combination therapy.

The results published at the 2024 ESMO suggest that ivonescimab may offer a significant improvement over existing treatment options for MSS/pMMR mCRC patients. The Phase III trial AK112-312/HARMONi-GI6 can potentially further validate the clinical benefits of ivonescimab in this setting, offering a novel first-line immunotherapy treatment option for patients with advanced mCRC.

Forward-Looking Statement of Akeso, Inc.

This announcement by Akeso, Inc. (9926.HK, “Akeso”) contains “forward-looking statements”. These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available, and 2 new drugs with 2 new indications are under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.

JSRPM Leverages AI and Advanced Machining to Counter Tariff Pressures

DONGGUAN, China, July 16, 2025 /PRNewswire/ — Amid mounting pressures from the ongoing U.S.–China tariff conflict, Chinese manufacturers are accelerating their digital transformation to remain competitive. Leading the charge is JSRPM , a precision machining and prototyping company that has integrated artificial intelligence into its manufacturing workflows through its platform www.jsrpm.com. With a focus on CNC machining, milling, rapid prototyping, and surface finishing, JSRPM is proving that technological innovation can overcome global trade headwinds.

Recent tariffs—some exceeding 100%—on critical exports like mechanical parts and electronics have disrupted traditional cost structures. In response, JSRPM has implemented AI to optimize production across key processes. AI now powers real-time adjustments to tool paths in CNC machines, predictive maintenance for milling and turning equipment, and intelligent quality control using vision inspection systems. These technologies have reduced defect rates by over 30% and cut lead times for custom parts by 25%, even for complex components involving multi-axis machining, EDM, or post-processing finishes like anodizing and polishing.

JSRPM’s AI tools also streamline front-end workflows, including automated quoting from 3D CAD files and dynamic scheduling of machining jobs. These capabilities allow the company to deliver high-quality metal and plastic components with shorter turnaround times, helping clients maintain continuity in their global supply chains—particularly those adopting “China+1” sourcing strategies.

Aligned with China’s “Made in China 2025″ initiative, JSRPM is building smart, connected factories that bridge physical production with digital intelligence. Its hybrid model of traditional machining excellence plus AI-driven control positions it as a trusted partner for industries such as robotics, automotive, medical devices, and electronics.

About JSRPM
JSRPM is a Dongguan-based smart manufacturing enterprise specializing in CNC precision parts, rapid prototyping, and custom machining solutions. Through www.jsrpm.com, the company provides global clients with fast, reliable, and AI-enhanced manufacturing services—from 3-axis to 5-axis machining and from low-volume prototyping to scalable production.

Contact
Gloria: Doris.wu@js-rapid.com
WeChat: +86 189 2585 8912
Address: 102, Building 2, No.1, South Jizhi Road, Dongguan City

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 16, 2025 /PRNewswire/ — In the newly released “Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report” by Global Accelerator for Paediatric formulations (GAP-f), the World Health Organization (WHO) host network, ziresovir (10mg) has been included in the PADO-RSV priority list. Ziresovir, developed by Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”), is the first and only RSV antiviral drug to be included in the list. This is the first time WHO has included an anti-RSV drug developed from China in the paediatric drug optimization priority list.

Filling a Global Gap: Ziresovir Leads RSV Antiviral Development

RSV is the leading pathogen of lower respiratory tract infections (LRTIs) in infants and young children globally, causing approximately 33 million cases of LRTIs, 3.6 million hospitalizations, and 101,400 deaths annually, with 97% of deaths occurring in low- and middle-income countries (LMICs). Despite the severe threat, current specific treatment options for RSV are extremely limited, and there is a clinical urgent need for safe, effective, and child-appropriate innovative drugs. The “Paediatric drug optimization for respiratory syncytial virus (PADO-RSV)” project initiated by WHO/GAP-f aims to systematically review the global R&D pipeline, clarify R&D priorities, and promote the development and accessibility of RSV prevention and treatment tools more suitable for the paediatric population. With its clear clinical value, child-friendly design, and good safety profile, ziresovir becomes the only product in the antiviral drug category selected for the PADO-RSV priority list, demonstrating its huge potential in the paediatric RSV treatment globally.

WHO pointed out in the report that ziresovir’s research results are of great significance to the global RSV treatment field and recommended conducting diverse clinical studies in broader populations to further verify its applicability and effectiveness.

ArkBio will actively respond to WHO’s advice with a plan to expand ziresovir’s clinical development in other countries and regions. By collaborating with international scientific institutions and public health organizations, ArkBio aims to rapidly advance the drug’s global registration and accessibility. Simultaneously, ArkBio is deeply aware of the importance of global public health, particularly concerned about the challenges faced by low- and middle-income countries. The company will formulate drug accessibility plans specifically for these countries to ensure ziresovir can be supplied at reasonable prices globally wherever it is needed, contributing to the prevention and treatment of RSV infection.

“ArkBio has a mission to ‘help patients inspire and thrive'”, Dr. Jim Wu, CEO of ArkBio, stated. “The inclusion of ziresovir in the WHO PADO-RSV priority list is not only an affirmation of the years of effort by ArkBio scientists, but also an inspiration for our corporate mission. The recognition of ziresovir would allow us to expedite its global development and realize the potential on the global stage. We will ensure the innovation can not only benefit patients in China but the very needed patients worldwide. This is not just our goal but our social responsibility. ArkBio will strive to contribute more to address global public health issues.”

About GAP-f

GAP-f stands for the Global Accelerator for Paediatric Formulations Network. Hosted by WHO, it operates throughout the drug development lifecycle to accelerate the research, development, and dissemination of optimized pediatric formulations. Identifying priorities is the first step toward a targeted R&D approach. Establishing a priority list of the most urgently needed pediatric formulations is crucial, as it helps focus the efforts and resources of researchers and suppliers on specific dosage forms and formulations that address children’s most critical needs.

About PADO

PADO stands for Paediatric Drug Optimization. It is a WHO’s legally binding international priority (based on WHA69.20 resolution) that accelerates the development of high-demand pediatric drugs by building consensus among regulators, funders, and manufacturers. It aims to identify priority products for R&D and define their ideal characteristics. It has been successfully implemented in areas including human immunodeficiency virus (HIV), hepatitis C, tuberculosis, COVID-19, antibiotics, neglected tropical diseases, and childhood cancers. These initiatives demonstrate that, against the backdrop of a fragmented and small pediatric drug market, such efforts hold potential and deliver tangible impacts in accelerating access to optimized formulations.

About Ziresovir

Ziresovir is a novel small-molecule RSV fusion (F) protein inhibitor. It binds to the pre-F protein conformation of the virus and prevents viral entry into human cells. Ziresovir can also suppress RSV viral transmission by blocking cell-to-cell fusion through the formation of “syncytia”, a characteristic event of RSV infection of host cells. It is the first oral anti-RSV drug that has completed a phase 3 pivotal clinical study with positive results. The phase 3 results have been published in The New England Journal of Medicine and The Lancet Child & Adolescent Health. Ziresovir has received Breakthrough Therapy designation by the National Medical Products Administration (NMPA) of China.

About ArkBio

ArkBio is a global biotech company focused on developing innovative therapeutics for respiratory, infectious, and pediatric diseases. Founded in 2014, it has built core technology platforms and a differentiated R&D pipeline through in-house R&D efforts and external collaboration. Key drug assets include ziresovir (AK0529), the first direct-acting RSV antiviral with positive pivotal phase III results, and Azstarys (AK0901), an FDA-approved ADHD therapeutic drug.

ArkBio has established strategic partnerships with several multinational pharmaceutical companies and academic institutes, including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions.

For more information, please visit: www.arkbiosciences.com
Investor Inquiries: IR@arkbiosciences.com

AbbVie’s 10th ‘Week of Possibilities’ Unites Employees Across Asia for Community Impact

–          880 AbbVie employees across 7 markets volunteered over 3,000 hours to support vulnerable groups.
–          Over 650 individuals benefited from 24 volunteer initiatives, delivered in partnership with 17 community organisations across the region.

SINGAPORE, July 16, 2025 /PRNewswire/ — AbbVie employees in Asia participated in the tenth Week of Possibilities (WOP), the AbbVie Foundation’s annual global volunteering programme, held in June and July. This unites our employees around the world with a single purpose to serve our local communities. 

880 employees across Singapore, Malaysia, Thailand, the Philippines, India, Taiwan region, and South Korea came together to engage in services tailored to the needs of their local communities through volunteer initiatives. Projects focused on supporting vulnerable groups, children, seniors, and individuals with health and social vulnerabilities.

“Our people power the change we want to see in the world. Through Week of Possibilities, we’re proud to stand alongside our partners across Asia to support the communities we live and work in, especially those who are often overlooked. Whether it’s helping children, seniors, people with disabilities, or protecting our environment, every action brings us closer to a more equitable, healthier future,” said Peggy Wu, Vice President, Asia, AbbVie.

In Thailand, employees focused on supporting students in a rural community with limited resources by rebuilding unsafe classrooms, providing lunches, and donating essentials. In the Philippines, volunteers contributed to food rescue efforts, preparing meals for communities with unmet needs and hosting a special Kasama Ka programme to raise awareness around food security and sustainability. The India team led a month-long series of engagements: organising a sports day for children experiencing homelessness in Mumbai, visiting a senior home for musical games and companionship, conducting art-based environmental workshops with children from low-income communities in Bangalore, and running a personal hygiene session at a children’s home in Delhi.

In Taiwan region and Malaysia, inclusive events such as stage performances, craft-making, and cycling activities empowered individuals with disabilities through confidence-building experiences. In Korea, employees supported people with disabilities through community outings, pop art portraits, and eco-friendly installations at care facilities. In Singapore, employees fostered social connections with seniors and vulnerable individuals through creative activities and heritage tours, while also supporting environmental sustainability through waterways clean-ups.

“We are deeply impressed by the passion and dedication of AbbVie volunteers, who actively participated and joyfully accompanied the disabled. This companionship brings not only encouragement but also respect and acceptance. Every time the volunteers cheer for the disabled, they help our foundation in promoting a more friendly treatment for people with disabilities,” said Li Shu Yu, staff member of the Eden Social Welfare Foundation, Taiwan.

Together, the WOP initiatives in Asia spanned healthcare, education, elderly support, environmental protection, and disability inclusion, reflecting the diverse needs of communities and the breadth of AbbVie’s commitment. At the heart of every activity was a shared belief that health equity starts with local action and that everyone has equal access to the opportunity to thrive.

Claire Chin, Area Head, Regulatory Affairs, AbbVie, shared, “June has always been my favourite month of the year at AbbVie. This year’s theme for AbbVie’s week of possibilities is advancing health equity. A lot of people might think of health equity as hospital visits and other charitable events. But in developed countries like Singapore, we tend to take our clean environment for granted. Before we consider advanced technologies and treatment options to support health, we have to first fulfil the basic human needs of hygiene, good health, and a good environment. To me, that’s where we can start to work towards creating a healthy living environment for each of us.”

Launched in 2014, AbbVie’s Week of Possibilities has grown into a cornerstone of the company’s global culture, engaging employees in voluntary actions and an annual celebration of giving back. Powered in part by the AbbVie Foundation, the initiative rallies employees worldwide to volunteer and make a meaningful impact in the communities where they live and work.

You can view images of AbbVie’s Week of Possibilities volunteer initiatives in Asia here.

AbbVie employees across Asia marked the 10th “Week of Possibilities” by partnering with non-profits to support local communities and advance health equity.
AbbVie employees across Asia marked the 10th “Week of Possibilities” by partnering with non-profits to support local communities and advance health equity.

Learn more about AbbVie’s Week of Possibilities at www.abbvie.com/givesback and AbbVie’s ongoing commitment to local communities in its 2024 ESG Action Report.

About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube..

About the AbbVie Foundation
The AbbVie Foundation is a 501(c)(3) nonprofit working to drive transformative change in communities worldwide so that everyone can live their healthiest life. We are committed to advancing health equity through innovative, community-led partnerships and through our employee impact programs around the world. For more information, please visit www.abbviefoundation.org.